Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Dermatologic 1CNS 1Breast 1

Conditions

Pathologic Processes 1Nervous System Neoplasms 1Nervous System Diseases 1Neoplastic Processes 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Glioma 1Central Nervous System Neoplasms 1Central Nervous System Diseases 1Breast Neoplasms 1Brain Neoplasms 1Brain Diseases 1

Interventions

pembrolizumab 43Nivolumab 24Gemcitabine 23Cyclophosphamide 22Paclitaxel 17Capecitabine 16fludarabine 15Ipilimumab 14aldesleukin 11Docetaxel 11130-nm albumin-bound paclitaxel 11Trastuzumab 10Cetuximab 10Bevacizumab 10Albumin-Bound Paclitaxel 9fludarabine phosphate 8Specimen Handling 8Interleukin-2 8Fluorouracil 8Cisplatin 8Biopsy 8Radiosurgery 7Oxaliplatin 7Irinotecan 7durvalumab 6avelumab 6Temozolomide 6Pemetrexed 6Leucovorin 6Carboplatin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Neoplasm Metastasis × glutathione pegylated liposomal doxorubicin × Clear all
NCT01386580 2015-01-22

An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.

BBB-Therapeutics B.V.

Phase 1/2 Completed
84 enrolled
BreastCNSDermatologicThoracic

Brain Diseases, Brain Neoplasms, Breast Neoplasms, Central Nervous System Diseases, Glioma, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Nervous System Diseases, Nervous System Neoplasms, Pathologic Processes, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡